This page is translated by Google and can contain errors. Go back to English.

News

Pancreatic cancer - joint event Anticancer Fund and Pancreatic Cancer Europe

Pancreatic cancer: joint efforts with Pancreatic Cancer Europe for more therapies

On June 25, 2024, Santiago de Compostela will host a gathering of experts aimed at enhancing treatment options for patients with pancreatic cancer.

Organised by the Anticancer Fund and Pancreatic Cancer Europe, and supported by the European Pancreatic Club, this Multistakeholder Meeting seeks to foster an inclusive dialogue among professionals.

Propranolol in clinical trial angiosarcoma

Exploring beta-blocker propranolol in angiosarcoma treatment

A clinical trial investigated propranolol, commonly used for high blood pressure, as a potential treatment for angiosarcoma, a rare and aggressive cancer. Funded by the Anticancer Fund, the study explored whether propranolol could help control tumour growth before traditional treatments start, aiming to increase the chances of survival.

#iDR24 - An international conference to move drug repurposing forward

The Anticancer Fund champions drug repurposing for cancer at the #iDR24 conference, taking place on March 6 and 7, 2024 in Barcelona. Identifying new uses for existing medicines, represents a significative opportunity for cancer patients.

Childhood solid tumours: first results of paediatric Metro-PD1-study

We present the initial findings of the French-Belgian Metro-PD1 study testing a treatment with nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumours. The study reveals new possible treatment avenues for paediatric solid tumours. The results were published in the European Journal of Cancer.

World Cancer Day - unveiling the impact of My Cancer Navigator, a beacon for cancer patients

Ahead of World Cancer Day, we highlight the impact My Cancer Navigator has had in the last five years. Our free information service has been a pillar of support for cancer patients globally.

Rare cancer drug development boosted by international research alliance